BioScrip Inc. (NASDAQ:BIOS) traded up 2.9% on Tuesday . The stock traded as high as $2.83 and last traded at $2.81, with a volume of 427,094 shares changing hands. The stock had previously closed at $2.73.

Separately, Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Friday, August 12th.

The stock’s market cap is $320.00 million. The firm’s 50 day moving average is $2.65 and its 200-day moving average is $2.41.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.05. The company earned $232.50 million during the quarter, compared to analyst estimates of $229.58 million. The company’s quarterly revenue was down 11.4% on a year-over-year basis. On average, analysts forecast that BioScrip Inc. will post ($0.27) earnings per share for the current year.

In other BioScrip news, Director Coliseum Capital Management, L bought 4,200,000 shares of the stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average price of $2.00 per share, with a total value of $8,400,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David W. Golding bought 12,500 shares of the stock in a transaction on Friday, June 17th. The shares were acquired at an average cost of $2.48 per share, for a total transaction of $31,000.00. Following the acquisition, the director now directly owns 42,500 shares in the company, valued at $105,400. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.